Stress, high blood pressure, smoking, pollution, fast foods, overweight,
excessive travelling, surgery, less movement are common features in our
modern life. These features are risky for blood clotting disorders.
According to WHO, over 29% of the total mortalities worldwide are due to
thrombosis. By the year, 2020 cardiovascular diseases (CVDs) may cause
an estimated 25 million deaths per year, thus antithrombotic therapy is
of great interest.
The available thrombolytic agents such as urokinase are highly
expensive, antigenic, quite unspecific, pyretogenic and hemorrhagenic.
Therefore, the production of fibrinolysing enzymes, which rapidly
dissolute thrombi within the vascular tree, without the detriments by
microorganisms, as described in this book, is the desirable aim of
today's research.